nach oben

International Urology and Nephrology

Erschienen in:

20.07.2018 | Nephrology - Original Paper

Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease–mineral and bone disorder?

verfasst von: Andreja Figurek, Goce Spasovski

Erschienen in: International Urology and Nephrology | Ausgabe 10/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The complexity of chronic kidney disease–mineral and bone disorder (CKD–MBD) led to many preclinical and clinical trials. The role of sclerostin in renal pathophysiology remained unresolved, and question whether sclerostin is related to cardiovascular (CV) outcome in patients with CKD is still open. Our aim was to evaluate the possible association between serum sclerostin levels and carotid intima-media thickness (CIMT) in CV pathophysiology through various CKD stages.

Methods

Eighty-eight patients in various CKD stages were involved in this analysis. CKD-EPI (Chronic kidney disease Epidemiology Collaboration Equation) was used to estimate glomerular filtration rate (eGFR). CKD–MBD parameters were determined in patients’ serum after an overnight fasting. Early atherosclerosis was assessed by ultrasound measurement of CIMT. In order to assess the association between serum sclerostin with other CKD–MBD parameters and CIMT, correlation and regression analyses were performed.

Results

Mean age was 62.84 ± 11.37 years and 56% were female. Mean values of serum sclerostin were 1.67 ± 0.44 ng/ml. Negative correlation was noticed with serum calcium and phosphate product (CaxP), alkaline phosphatase (ALP), intact parathyroid hormone (iPTH), serum creatinine, and HbA1c level. There was no association with FGF23, CIMT, and carotid atherosclerotic plaque occurence. Serum levels of sclerostin were significantly higher in female patients compared to males (p < 0.001).

Conclusion

Advanced CKD showed a trend of declining sclerostin levels and significantly higher CIMT levels. Serum sclerostin was not associated with CIMT. More studies are needed in order to reveal the exact role of sclerostin in the complexity of CKD–MBD pathophysiological mechanism.

Fliser D, Kollerits B, Neyer U et al (2007) Fibroblast growth factor 23 predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. JASN 18(9):2600–2608CrossRefPubMed

Wang X, Yuan L, Zhang J, Hao L, Wang D (2017) Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3-5D. Nephrology 22:286–292CrossRefPubMed

Kanbay M, Siriopol D, Saglam M et al (2014) Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients. J Clin Endrocrinol Metab 99:E1854–E1861CrossRef

Kanbay M, Solak Y, Siriopol D et al (2016) Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. Int Urol Nephrol 48:2029–2042CrossRefPubMed

Cejka D, Marculescu R, Kozakowski N et al (2014) Renal elimination of sclerostin increases with declining kidney function. J Clin Endocrinol Metab 99:248–255CrossRefPubMed

Brandenburg VM, Kramann R, Koos R et al (2013) Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study. BMC Nephrol 14:219CrossRefPubMedPubMedCentral

Morales-Santana S, Garcia-Fontana B, Garcia-Martin A et al (2013) Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 36:1667–1674CrossRefPubMedPubMedCentral

Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE (2014) The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-I) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Diabetes Vasc Dis Res 11(1):48–52CrossRef

Bruzzese A, Lacquaniti A, Cernaro V et al (2016) Sclerostin levels in uremic patients: a link between bone and vascular disease. Ren Fail 38(5):759–764CrossRefPubMed

10.

Sinha M, Turner C, Dalton RN et al (2012) Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3–5. Nephrol Dial Transplant 27:4361–4368CrossRefPubMed

11.

Yamashita H, Yamazaki Y, Hasegawa H et al (2005) Fibroblast growth factor-23 in patients with Graves’ disease before and after antithyroid therapy: its important role in serum phosphate regulation. J Clin Endocrinol Metab 90(7):4211–4215CrossRefPubMed

12.

Yamazaki Y, Okazaki R, Shibata M et al (2002) Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960CrossRefPubMed

13.

Kirkpantur A, Balci M, Turkvatan A, Afsar B (2016) Serum sclerostin levels, arteriovenous fistula calcification and 2-years all-cause mortality in prevalent hemodialysis patients. Nephrologia 36(1):24–32

14.

Тоuboul PJ, Hennerici MG, Meairs S et al (2007) Mannheim carotid intima-media thickness consensus (2004–2006). Cerebrovasc Dis 23(1):75–80CrossRef

15.

Brkljacic B (2010) Vascular ultrasound. Medicinska naklada, Zagreb

16.

Zeng C, Guo C, Cai J, Tang C, Dong Z (2017) Serum sclerostin in vascular calcification and clinical outcome in chronic kidney disease. Diabetes Vasc Dis Res. https://doi.org/10.1177/1479164117742316 CrossRef

17.

Tartaglione L, Pasquali M, Rotondi S et al (2017) Interactions of sclerostin with FGF23, soluble klotho and vitamin D in renal transplantation. PLoS ONE 12(5):e0178637CrossRefPubMedPubMedCentral

18.

Costa A, Bilezikian JP, Lewiecki EM (2015) The potential use of antisclerostin therapy in chronic kidney disease-mineral and bone disorder. Curr Opin Nephrol Hypertens 24:324–329PubMed

19.

Behets GJ, Viaene L, Meijers B et al (2017) Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. PLoS ONE 12(5):e0176411CrossRefPubMedPubMedCentral

20.

Sabbagh Y, Graciolli FG, O’Brien S et al (2012) Repression of osteocyte Wnt/b-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27(8):1757–1772CrossRefPubMed

21.

Robling AG, Niziolek PJ, Baldridge LA et al (2008) Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J Biol Chem 283:5866–5875CrossRefPubMed

22.

Delanaye P, Krzesinski JM, Warling X et al (2014) Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract 128:127–134CrossRefPubMed

23.

Schiavi SC, Moyses RM (2016) Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast beta-catenin pathway. Kidney Int 90:17–20CrossRefPubMed

24.

Pelletier S, Dubourg L, Carlier MC, Hadj-Aissa A, Fouque D (2013) The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 8:819–823CrossRefPubMedPubMedCentral

25.

Lv W, Guan L, Zhang Y et al (2016) Sclerostin as a new key factor in vascular calcification in chronic kidney disease stages 3 and 4. Int Urol Nephrol 48:2043–2050CrossRefPubMed

26.

Figurek A (2017) The role of fibroblast growth factor 23 in early diagnosis of chronic kidney disease mineral and bone disorder. Dissertation, University of Banja Luka

27.

Graciolli FG, Neves KR, Barreto F et al (2017) The complexity of chronic kidney disease-mineral and bone disorder acreoss stages of chronic kidney diease. Kindey Int 91:1436–1446CrossRef

28.

Kirkpantur A, Balci M, Turkvatan A, Afsar B (2015) Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J 8(6):737–743CrossRefPubMedPubMedCentral

29.

Qureshi AR, Olauson H, Witasp A et al (2015) Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int 88:1356–1364CrossRefPubMed

30.

Morena M, Jaussent I, Dupuy AM et al (2015) Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant 30:1345–1356CrossRefPubMed

31.

Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P (2013) Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab 98:3221–3228CrossRefPubMed

32.

Torino C, Pizzini P, Cutrupi S et al (2017) Active vitamin D treatment in CKD patients raises serum sclerostin and this effect is modified by circulating pentosidine levels. Nutr Metab Cardiovasc Dis 27:260–266CrossRefPubMed

Titel: Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease–mineral and bone disorder?
verfasst von: Andreja Figurek
Goce Spasovski
Publikationsdatum: 20.07.2018
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 10/2018
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-1935-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2018

Sclerostin: a biomarker for chronic kidney disease and vascular disease with added or independent value?

Nephrotoxicity of iodixanol versus iopamidol in patients undergoing peripheral angiography with or without endovascular therapy

Can single positive core prostate cancer at biopsy be considered a low-risk disease?

Cancer survivorship issues with radiation and hemorrhagic cystitis in gynecological malignancies

Discontinuation of renal replacement therapy in critically ill patients with severe acute kidney injury: predictive factors of renal function recovery